Clinical Trials

Inclusion Criteria:

• Male and female subjects ≥ 18 years of age.
• Clinical diagnosis of NASH assessed by the presence of body imaging criteria [ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI)], or liver biopsy up to six months prior to enrollment without suspicious nodules or cancer.
• Screening transient elastography (Fibroscan®) liver stiffness ≥ 12 kPa (which correlates with F3 fibrosis and more) and < 25 kPa (63). Historic transient elastography (Fibroscan®)within 0 - 4 weeks prior to the date of the screening visit is acceptable.
• Controlled attenuation parameter score of ≥ 270 dB/m or historic liver biopsy within 0 - 6 months prior to the date of the screening visit consistent with NASH (defined as the presence of steatosis, inflammation, and ballooning), with stage 3-4 fibrosis according to the NASH Clinical Research Network classification (or equivalent).
• Participants must have adequate marrow, organ, hepatic and renal function as defined below:
  • Leukocytes ≥3,000/microliter;
  • Absolute neutrophil count ≥1,500/microliter;
  • Platelets ≥75,000/microliter;
  • Total bilirubin within normal institutional limits unless the patient has Gilbert’s syndrome;
  • AST (SGOT)/ALT (SGPT) ≤8× institutional upper limit of institutional limits;
  • Glomerular filtration rate >30 ml/min INR ≤1.3 unless the patient is on a therapeutic medication.
• ECOG performance status ≤ 2 (Karnofsky ≥60%; see Appendix A).
• The effects of lisinopril has been shown to be teratogenic in animal models. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
• Ability to understand and the willingness to sign a written informed consent document. If a participant has impaired decision-making capacity (IDMC), their legal representative may replace them in this process.
• Systolic blood pressure ≥90 and ≤160 mm/Hg. Diastolic blood pressure ≥60 and ≤110 mm/Hg.

Exclusion Criteria:

• Prior or current use of an ACEi or ARB within 0 - 24 weeks prior to enrollment.
• Glomerular filtration rate ≤ 30 ml/min (for both male and female participants).
• History of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding.
• History of other causes of liver disease, including but not limited to alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders (primary biliary cholangitis, primary sclerosing cholangitis, or autoimmune hepatitis), drug-induced hepatotoxicity, Wilson’s disease, iron overload, or alpha-1-antitryspin deficiency.
• History of liver transplantation.
• History of HCC diagnosis.
• History of weight reduction surgery in the past 2 years or planned during the study.
• Within 6 months prior to the date of the screening visit, there must be no history of the following cardiac events: unstable angina; myocardial infarction, coronary artery bypass surgery or coronary angioplasty; transient ischemic attack or cerebrovascular accident; emergency room visit or hospitalization for confirmed cardiovascular disease.
• Participants taking vitamin E ≥800 IU/day must be on a stable dose, defined as no changes in prescribed dose, new vitamin E-containing medications, or discontinuation for at least 180 days prior to the date of the screening visit and throughout study participation.
• Participants taking anti-diabetic medications must be on a stable dose for at least 90 days prior to the date of the screening visit and in the period between the date of the screening visit and enrollment.
• Current alcohol consumption >21 oz/week for males or >14 oz/week for females [1 oz/30 mL of alcohol is present in one 12 oz/360 mL beer, 4 oz/120 mL glass of wine, and a 1oz/30 mL measure of 40proof (20%) alcohol].
• Participants may not be receiving any other investigational agents, at the time of the screening visit, or in the prior 30 days, or within 5 half-lives of the prior investigational agent (whichever is longer).
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to lisinopril.
• Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
• History of HIV infection. HIV patients may develop fatty liver as well as advanced fibrosis due to many causes including metabolic syndrome, hyperuricemia, HIV-related lipodystrophy, genetic polymorphisms, medications, and HIV itself (64). As the natural history of fatty liver in this population is largely unknown, these patients will be excluded from this study.
• Women who are pregnant or breastfeeding. Pregnant women are excluded from this study because lisinopril is an ACE Inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with lisinopril. Breastfeeding should be discontinued if the mother is treated with lisinopril.
• Systolic blood pressure ≥161 mm/Hg. Diastolic blood pressure ≥111 mm/Hg.
• Participants taking Lithium.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/11/22. Questions regarding updates should be directed to the study team contact.